Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK‐rearranged non‐small cell lung cancer

Gilteritinib is a multitarget tyrosine kinase inhibitor (TKI), approved for the treatment of FLT3‐mutant acute myeloid leukemia, with a broad range of activity against several tyrosine kinases including anaplastic lymphoma kinase (ALK). This study investigated the efficacy of gilteritinib against AL...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, Chihiro, Ichihara, Eiki, Nishi, Tatsuya, Morita, Ayako, Hara, Naofumi, Takada, Kenji, Nakasuka, Takamasa, Watanabe, Hiromi, Kano, Hirohisa, Nishii, Kazuya, Makimoto, Go, Kondo, Takumi, Ninomiya, Kiichiro, Fujii, Masanori, Kubo, Toshio, Ohashi, Kadoaki, Matsuoka, Ken‐ichi, Hotta, Katsuyuki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637052/
https://www.ncbi.nlm.nih.gov/pubmed/37715310
http://dx.doi.org/10.1111/cas.15958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637052/
https://www.ncbi.nlm.nih.gov/pubmed/37715310
http://dx.doi.org/10.1111/cas.15958

Ejemplares similares